Is Self-Affirming GRAS Off the Menu?

March 12, 2025

Reading Time : 2 min

United States Department of Health and Human Services (HHS) Secretary Kennedy recently directed the U.S. Food and Drug Administration (FDA) to consider rulemaking to revise its longstanding regulations and guidance governing the oversight of food ingredients to eliminate the ability of individuals and companies to self-affirm that their ingredients are Generally Recognized as Safe (GRAS). This would mark a massive shift in how new food ingredients are introduced to the market.

In 1958, Congress enacted the Food Additives Amendment to the Food, Drug and Cosmetic Act (FDCA). These amendments required that “food additives” receive premarket approval from FDA, unless they were “substances that are generally recognized, among experts qualified by scientific training and experience to evaluate their safety as having been adequately shown… to be safe under the conditions of their intended use.” Such substances are considered to be “generally recognized as safe”.[1]

The agency’s approach to GRAS determinations has evolved over the intervening decades, with the last major change coming in 2016 with the publication of what is referred to as the final GRAS rule. Under this rule, “any person may notify FDA of a view that a substance is not subject to the premarket approval requirements….” 21 C.F.R. § 170.205. This provision establishes a voluntary pathway for industry to submit a GRAS notification to FDA—in other words, a person or company may make an “independent conclusion of GRAS status” without also making a submission to FDA (though FDA strongly encourages submitting notice to the agency for review).[2]This process, otherwise known as “self-affirming,” is the subject of Secretary Kennedy’s order.  

In his order, Secretary Kennedy states that “[f]or far too long, ingredient manufacturers and sponsors have exploited a loophole that has allowed new ingredients and chemicals, often with unknown safety data, to be introduced into the U.S. food supply without notification to the FDA or the public… Eliminating this loophole will provide transparency to consumers, [and] help get our nation’s food supply back on track….” Further still, the order notes that HHS is “committed to working with Congress to explore ways legislation can completely close the GRAS loophole.”

While details are sparse, removal of the self-affirming pathway would presumably require rulemaking or legislation. In the interim, FDA could start exercising greater scrutiny of self-affirming GRAS determinations. An end to the self-affirmation process would also create significantly more work for the agency in evaluating proposed new ingredients, at a time when the administration is attempting to drastically shrink the FDA work force.


[1] Note that substances used in food before 1958 may also be considered GRAS based on a determination made through experience based on common use in food. 21 C.F. R. § 170.30.

[2] 81 Fed. Reg. 54,960, 54,966 (Aug. 17, 2016).

Share This Insight

Previous Entries

Eye on FDA

June 10, 2026

On June 2, 2026, the U.S. Food and Drug Administration (FDA) issued draft guidance on how drug and device companies may communicate health care economic information (HCEI) with payors (e.g., health insurance companies), formulary committees (e.g., pharmacy and therapeutics committees) and similar entities. The guidance, Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers, is now open for comment.

...

Read More

Eye on FDA

May 19, 2026

On May 12, 2026, the Food and Drug Administration (FDA) published a notice in the Federal Register requesting comment on the agency’s efforts related to drug repurposing to help address unmet medical needs. In this request for information (RFI), FDA is seeking input to identify potential new uses for FDA-approved drugs—such as a new indication or a new population—to help accelerate the availability of treatments for unmet medical needs. Stakeholders are encouraged to submit priority disease areas and potential candidates for drug repurposing, particularly in cases where there is a lack of commercial incentive to pursue labeling changes or a significant unmet need.

...

Read More

Eye on FDA

May 14, 2026

As medical chatbots proliferate, a new Pennsylvania lawsuit highlights a developing trend of states leading health artificial intelligence (AI) enforcement efforts, while the Food and Drug Administration (FDA) appears to be on the sidelines.

...

Read More

Eye on FDA

May 13, 2026

On May 12, 2026, the U.S. Food and Drug Administration (FDA) announced a major milestone in its approach to post-market oversight of chemicals in the food supply, finalizing a new proactive food chemical safety post-market assessment program and releasing two foundational papers: the “Enhanced Systematic Process for Post-Market Assessment of Chemicals in Food” and the “Tool for the Prioritization of Food Chemicals for Post-Market Assessment.”

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.